scispace - formally typeset
M

Michael A. Rogawski

Researcher at University of California, Davis

Publications -  372
Citations -  25041

Michael A. Rogawski is an academic researcher from University of California, Davis. The author has contributed to research in topics: Epilepsy & Neuroactive steroid. The author has an hindex of 83, co-authored 370 publications receiving 23226 citations. Previous affiliations of Michael A. Rogawski include Massachusetts Institute of Technology & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

The neurobiology of antiepileptic drugs.

TL;DR: The subtle biophysical modifications in channel behaviour that are induced by AEDs are often functionally opposite to defects in channel properties that are caused by mutations associated with epilepsy in humans.
Journal ArticleDOI

d-Serine is an endogenous ligand for the glycine site of the N-methyl-d-aspartate receptor

TL;DR: D-serine is an endogenous modulator of the glycine site of NMDA receptors and fully occupies this site at some functional synapses and greatly attenuates NMDA receptor-mediated neurotransmission as assessed by using whole-cell patch-clamp recordings or indirectly by using biochemical assays of the sequelae of NMda receptor- mediated calcium flux.
Journal Article

Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds.

TL;DR: Antiepileptic drug pheny toin potentiates GABA in the rat cuneate nucleus and its metabolite as potent inhibitors of microsomal metabolism of phenytoin and carbamazepine.
Journal ArticleDOI

Glia and epilepsy: excitability and inflammation

TL;DR: This review critically evaluates the role of glia-induced hyperexcitability and inflammation in epilepsy and points to a significant contribution by non-neuronal cells, the glia--especially astrocytes and microglia--in the pathophysiology of epilepsy.
BookDOI

Jasper's basic mechanisms of the epilepsies

TL;DR: This work presents a meta-anatomy of the immune response to the presence of EMTs in the central nervous system, which highlights the need to understand more fully the role of immune checkpoints in EMT treatment.